SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Response Biomedical (V.RBM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dick Martin who wrote (533)11/29/2004 4:34:16 PM
From: Starowl  Read Replies (1) of 655
 
This bit of news is very positive--an agreement with 3M's Medical Division to develop tests based on the RAMP technology.

"Response Biomedical and 3M Collaborate on Infectious Disease Test
Monday November 29, 4:22 pm ET

"VANCOUVER, Nov. 29 /PRNewswire-FirstCall/ - Response Biomedical Corp. (TSX-V: RBM - News) and 3M Company (NYSE: MMM - News) through its Medical Division, today announced that the two companies have entered into a co-development agreement whereby 3M will fund the development of a new rapid, point-of-care microbiology test in the area of infection prevention based on Response Biomedical's RAMP technology. The parties intend to enter into a further supply agreement whereby Response Biomedical will manufacture and 3M will exclusively market a line of microbiology tests.

"3M Medical Division is part of a world class company with an extraordinary ability to develop and commercialize promising new technologies," states Bill Radvak, President and CEO, Response Biomedical Corp. "This unique combination of technology and expertise in infectious disease testing will help us introduce a broader product portfolio to enhance patient outcomes and improve productivity for physicians and health care providers."

"Conventional diagnosis of infectious diseases is time intensive, and prohibits immediate intervention and early treatment. Clinical infectious disease testing at the point-of-care is expected to improve patient outcomes by enabling physicians to make informed medical decisions rapidly."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News